WAT · Earnings call · 2026Q2T · Full report
Diagnostics Replacement Opportunity
WATERS CORP /DE/ · 2026-08-04 · Importance 34 · Surprise 42 · In source text
The BACTEC FXI blood culture system received FDA 510(k) clearance and began placements in Japan and Europe, with U.S. commercialization underway. FXI detects bloodstream infections up to three hours faster than competing systems, provides two- to three-times the input capacity and can deliver up to 10 days of annualized time savings. Waters identified more than 12,000 aged BACTEC systems past due for replacement, including roughly 4,500 in the U.S. Early customer feedback included an 80% reduction in hands-on time at a Japanese site. Management expects FXI to become a multiyear replacement growth engine in microbiology.
Key facts
- Over 12,000 aged BACTEC systems are past due for replacement, with about 4,500 in the U.S.
- BACTEC FXI detects bloodstream infections up to three hours faster than competing systems and offers two- to three-times the input capacity
- One early adopter site in Japan reported an 80% reduction in hands-on time after switching to FXI
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | contingent | — | Over 12,000 aged BACTEC systems are past due for replacement, with about 4,500 in the U.S. |
| revenue | positive | probable | — | BACTEC FXI detects bloodstream infections up to three hours faster than competing systems and offers two- to three-times the input capacity |